Benefits of a 12-week lifestyle modification program including diet and combined aerobic and resistance exercise on albuminuria in diabetic and non-diabetic Japanese populations

Clinical and Experimental Nephrology

Volumn 19, Issue 6, 2015, Pages 1079-1089

  Yamamoto Kabasawa, Keiko ^a   Hosojima, Michihiro ^a   Yata, Yusuke ^a   Saito, Mariko ^b   Tanaka, Noriko ^b   Tanaka, Junta ^a   Tanabe, Naohito ^c   Narita, Ichiei ^a   Arakawa, Masaaki ^b   Saito, Akihiko ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niigata Institute for Health and Sports Medicine   (Japan)

^c UNIVERSITY OF NIIGATA PREFECTURE   (Japan)

Author keywords

Albuminuria; Hypertension; Lifestyle modification; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; RENIN INHIBITOR; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AEROBIC EXERCISE; ALBUMINURIA; ARTICLE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; DIET; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE TRAINING; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; AGED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET THERAPY; EXERCISE; JAPAN; KINESIOTHERAPY; LIFESTYLE; METABOLISM; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ALBUMINURIA; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EXERCISE; EXERCISE THERAPY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; JAPAN; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATIENT SAFETY; RESISTANCE TRAINING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951906104     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1103-5     Document Type: Article

References (27)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–60.
3. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17:S81–5.
4. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet. 1974;1:1190–2.
5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Prevention of renal and vascular end stage disease (PREVEND) study group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.
6. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.
7. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol. 2007;27:287–93.
8. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–9.
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
10. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus CR, Myers V, Nauta M, Rodarte RQ, Sparks L, Thompson A, Earnest CP. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2010;304:2253–62.
11. Davidson LE, Hudson R, Kilpatrick K, Kuk JL, McMillan K, Janiszewski PM, Lee S, Lam M, Ross R. Effects of exercise modality on insulin resistance and functional limitation in older adults: a randomized controlled trial. Arch Intern Med. 2009;169:122–31.
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.
13. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001;9:228S–33S.
14. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–92.
15. Cubeddu LX, Alfieri AB, Hoffmann IS. Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese “normoalbuminuric” non-diabetic subjects. Am J Hypertens. 2008;21:105–10.
16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
17. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202.
18. Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007;56:1727–30.
19. Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, Suzuki K, Kiuchi Y, Iwamoto Y. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care. 2009;32:1518–20.
20. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19:2784–8.
21. MacIsaac RJ, Ekinci EI, Jerums G. Progressive diabetic nephropathy. How useful is microalbuminuria?: contra. Kidney Int. 2014;86:50–7.
22. Hao Z, Konta T, Takasaki S, Abiko H, Ishikawa M, Takahashi T, Ikeda A, Ichikawa K, Kawata S, Kato T, Kubota I. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. Intern Med. 2007;46:341–6.
23. Tanaka S, Takase H, Dohi Y, Kimura G. The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study. BMC Res Notes. 2013;6:256.
24. Wang X, Armando I, Upadhyay K, Pascua A, Jose PA. The regulation of proximal tubular salt transport in hypertension: an update. Curr Opin Nephrol Hypertens. 2009;18:412–20.
25. Lewis EJ, Lewis JB. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol. 2003;1:1–8.
26. Spanos G, Kalaitzidis R, Karasavvidou D, Pappas K, Siamopoulos KC. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study. J Renin Angiotensin Aldosterone Syst. 2013;14:315–21.
27. Bellinghieri G, Savica V, Santoro D. Renal alterations during exercise. J Ren Nutr. 2008;1:158–64.